MGNX

NASDAQ open

MacroGenics

1.97 USD
▼-0.01-0.51%
盘后 2.37 0.00%
2026-11-20
市值
$125.26M
市盈率
—
EPS
-0.81
股息率
—
52 周区间
1.32 – 5.08
成交量
1.00M
Beta
1.32
目标价
8.00
52W 低 1.3252W 高 5.08
价格走势

公司简介

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG...